Sökning: onr:"swepub:oai:DiVA.org:umu-191090" >
Gestational weight ...
-
Molin, JohannaUmeå universitet,Obstetrik och gynekologi
(författare)
Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome : A longitudinal, placebo-controlled study
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2021-12-27
-
John Wiley & Sons,2022
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-191090
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-191090URI
-
https://doi.org/10.1111/1471-0528.17042DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Objective: To explore mechanisms that modulate gestational weight gain (GWG) in women with polycystic ovary syndrome (PCOS) and healthy controls.Design: Sub-sample of randomised controlled trials (PCOS) combined with a prospective cohort (controls).Setting: Eleven Norwegian, Swedish, and Icelandic hospitals.Population: Pregnant women with PCOS treated with metformin (PCOS-M, n = 36) or placebo (PCOS-P, n = 37), and healthy pregnant women (HC, n = 15).Methods: Serum levels of the appetite regulating hormones leptin, ghrelin, allopregnanolone, and soluble leptin receptor (sOB-R) were determined in the first and third trimesters.Main Outcome Measures: Excessive GWG (eGWG) relative to body mass index according to Institute of Medicine (IOM) guideline. Serum leptin/sOB-R ratio, or free-leptin-index (FLI), as biomarker of leptin sensitivity. Serum ghrelin and allopregnanolone levels.Results: The overall prevalence of eGWG was 44% (38/86). Women with eGWG had higher first and third trimester FLI (P < 0.001), and lower third trimester allopregnanolone levels (P = 0.003) versus women with non-eGWG. The prevalence of eGWG was lower in PCOS-M versus PCOS-P (28% versus 62%, odds ratio = 0.4, 95% CI 0.2–0.8, P = 0.005). FLI decreased during pregnancy in PCOS-M (P = 0.01), but remained unaltered in PCOS-P and HC. Ghrelin and allopregnanolone levels were comparable in PCOS-M, PCOS-P and HC throughout pregnancy.Conclusion: Excessive GWG is associated with enhanced leptin resistance, and attenuated physiological increase in serum allopregnanolone levels during pregnancy. Metformin reduces the risk for eGWG and improves leptin sensitivity in pregnant women with PCOS.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Vanky, EszterDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Obstetrics and Gynaecology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
(författare)
-
Løvvik, Tone S.Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Obstetrics and Gynaecology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
(författare)
-
Dehlin, EvaUmeå universitet,Obstetrik och gynekologi(Swepub:umu)evde0002
(författare)
-
Bixo, MarieUmeå universitet,Obstetrik och gynekologi(Swepub:umu)mabi0001
(författare)
-
Umeå universitetObstetrik och gynekologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:British Journal of Obstetrics and Gynecology: John Wiley & Sons129:7, s. 1112-11211470-03281471-0528
Internetlänk
Hitta via bibliotek
Till lärosätets databas